Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension
Luciana Neves Cosenso-Martin, Lais Yumi Takaoka, Jose Fernando Vilela-Martin Internal Medicine Division, State Medical School at Sao Jose do Rio Preto (FAMERP), Hospital de Base, Sao Jose do Rio Preto, Sao Paulo, BrazilCorrespondence: Jose Fernando Vilela-MartinState Medical School at Sao Jose do Ri...
Guardado en:
Autores principales: | Cosenso-Martin LN, Takaoka LY, Vilela-Martin JF |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b35bd148569741d0b3a3712e6c77151a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010) -
The Effect of Bioactive Polyphenols from <i>Anacardium occidentale</i> Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities
por: Nur Imanina Abdullah Thaidi, et al.
Publicado: (2020) -
Conceptos actuales en hipertensión arterial
por: Lama T,Alexis, et al.
Publicado: (2001) -
The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh CJ, et al.
Publicado: (2014) -
Gliptins vs. Milk-derived Dipeptidyl-Peptidase IV Inhibiting Biopeptides: Physicochemical Characterization and Pharmacokinetic Profiling
por: Jorge Andrés Barrero, et al.
Publicado: (2021)